India, April 11 -- image credit- shutterstock

The Indian pharmaceutical market is witnessing a dramatic transformation following the patent expiry (on March 11 2025) of Empagliflozin (sold under the brand name Jardiance by Boehringer Ingelheim), used for treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control and to reduce the risk of cardiovascular death in patients with established cardiovascular disease.

Jardiance (empagliflozin), a SGLT2 inhibitor, was approved in 2014 for type 2 diabetes and later expanded to include heart failure and kidney disease indications. In 2023, the druggenerated$8 billion in global sales, according to reports.

Following the patent expiry of Empagli...